An observational study in Cushing Disease, sponsored by Centre Hospitalier Universitaire de Nīmes. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational
Automated immunodosage methods (Roche Elecsys cortisol and IDS cortisol dosing kits) offer a simple and inexpensive technology routinely used in a medical biology laboratory. They can be used to define robust diagnostic thresholds for salivary cortisol for the diagnosis of Cushing's syndrome and pseudo-Cushing combining the three tests performed as part of the patient's usual management. (ie two urinary free cortisol (UFC), the dexamethasone suppression test, and Diurnal variation of plasma cortisol).
64 studies on the registry are indexed under Pituitary ACTH Hypersecretion; 16 are open to participants now.
This study's planned enrollment of 380 is above the median of 131 across 20 observational studies indexed under Pituitary ACTH Hypersecretion.
Browse Pituitary ACTH Hypersecretion studies →Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 90 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The target population of the study is patients suspected of hypercorticism. The study's source population will correspond to all patients (men and women) between the ages of 18 and 65 hospitalized in the metabolic and endocrine disorders department of CHU Nîmes for hypercorticism assessment in primary diagnosis or in a follow-up report.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The patient has a cardiovascular or metabolic state against the indication of dexamethasone
- Patient with DFG \< 30 ml/min/1.73 m2
The patient is taking corticoids (oral, inhaled, intra-venous or cutaneous)
.Patient exposed to interfering treatments (Itraconazole, ritonavir, megestrol acetate, medroxyprogesterone acetate, TSH, estrogen-progestogen pill, hormonal coil)
Diagnostic Test: Blood test · Diagnostic Test: 24-hour Urine test · Diagnostic Test: Saliva swab · Diagnostic Test: Dexamethasone test
Plasma cortisol level test
Urinary free cortisol test
salivette® for salivary cortisol quantification
Dectancyl® 2 x 0.5 mg tablets (total 1 mg)
Salivary cortisol measured by Roche Elecsys cortisol kit
nmol/l
Time frame: Day 1 (at screening)
Salivary cortisol measured by IDS cortisol dosing kit at screening
nmol/l
Time frame: Day 1 (at screening)
Salivary cortisol measured by Roche Elecsys cortisol kit
nmol/l
Time frame: Day 2 and Day 3
Salivary cortisol measured by IDS cortisol dosing kit
nmol/l
Time frame: Day 2 and Day 3
Salivary cortisol measured measured by LC-MS/MS
nmol/l
Time frame: Day 1, 2 and 3
Dexamethasone suppression test
µg/l and nmol/l (cut-off for diagnosis: 50nmol/l)
Time frame: Day 4
Diurnal variation of plasma cortisol
Roche Elecsys cortisol kiet; µg/l and nmol/l (cut-off for diagnosis: 200nmol/l)
Time frame: Day 3
Urinary free cortisol
Radioimmunoassay; µg/l and nmol/l
Time frame: Day 3
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pituitary ACTH Hypersecretion →
Centre Hospitalier Universitaire de Nīmes →